| pubmed-article:2520453 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2520453 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:2520453 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2520453 | lifeskim:mentions | umls-concept:C0010453 | lld:lifeskim |
| pubmed-article:2520453 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:2520453 | lifeskim:mentions | umls-concept:C1518174 | lld:lifeskim |
| pubmed-article:2520453 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:2520453 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2520453 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2520453 | pubmed:dateCreated | 1992-5-12 | lld:pubmed |
| pubmed-article:2520453 | pubmed:abstractText | In tissue culture, azelaic acid (C9) has been shown to have an anti-proliferative and cytotoxic effect on human and murine malignant melanocytes, with inhibition of mitochondrial oxido-reductase enzymes and DNA synthesis, and damage to mitochondria. Recent reports of effects on differentiation of normal keratocytes have led to the present study of its effects on a squamous carcinoma cell line. Cells were exposed to single doses of disodium salts of azelaic (C9(2)Na) and adipic (C6(2)Na) acids at concentrations of 10(-2)M and 5 x 10(-2)M for 48 hrs. Only C9(2)Na at 5 x 10(-2) M for 4 hrs., and longer, significantly affected proliferation, and the cells exhibited massive swelling of mitochondria with loss of cristae. The results further confirm the probable value of azelaic acid as a general anti-tumoral agent rather than a specifically melanocytotoxic one. They could justify clinical studies on the effect of topical azelaic acid therapy on squamous cell carcinoma in vivo. | lld:pubmed |
| pubmed-article:2520453 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520453 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2520453 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520453 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2520453 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520453 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520453 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520453 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520453 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520453 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2520453 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2520453 | pubmed:issn | 0213-3911 | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:BreathnachA... | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:PassiSS | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:Nazzaro-Porro... | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:PicardoMM | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:RobinsE JEJ | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:BhasinY PYP | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:PätzoldH CHC | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:EthridgeL BLB | lld:pubmed |
| pubmed-article:2520453 | pubmed:author | pubmed-author:DaridanM EME | lld:pubmed |
| pubmed-article:2520453 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2520453 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:2520453 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2520453 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2520453 | pubmed:pagination | 167-71 | lld:pubmed |
| pubmed-article:2520453 | pubmed:dateRevised | 2010-8-25 | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:meshHeading | pubmed-meshheading:2520453-... | lld:pubmed |
| pubmed-article:2520453 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2520453 | pubmed:articleTitle | Effect of dicarboxylic (C6 and C9) acids on a human squamous carcinoma cell line in culture. | lld:pubmed |
| pubmed-article:2520453 | pubmed:affiliation | Department of Anatomy and Cell Biology, St. Mary's Hospital, Medical School, London, U.K. | lld:pubmed |
| pubmed-article:2520453 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2520453 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
